--Q3 2026 total revenue of
--Revises full year 2026 revenue guidance to
--Advances innovation pipeline with NeuroPace Remote Care™ FDA submission and upcoming IGE PMA-S Amendment, supporting significant long-term growth opportunities--
Third Quarter 2026 Financial Highlights
- Total revenue of
$23.1 million in the third quarter of 2026 - RNS System revenue of
$22.9 million in the quarter, representing 1.4% growth compared to the third quarter of 2025 - Net loss in the third quarter of 2026 was
($3.3) million compared to($4.9) million in the third quarter of 2025 - Adjusted EBITDA of
$0.4 million for the third quarter of 2026, compared to($1.3) million in the third quarter of 2025
Third Quarter 2026 Operational & Strategic Highlights
- Completed a Submission Issue Request (SIR) meeting with the FDA in October regarding the Company’s premarket approval (PMA) supplement for idiopathic generalized epilepsy (IGE).
NeuroPace is incorporating the agency’s feedback into an amendment and expects to submit the amendment around year end. - Submitted a PMA-Supplement for Remote Care to the FDA, with a planned 180-day review cycle. Remote Care is designed to enable physicians to program the RNS System through telehealth, reducing the need for in-person visits and helping address travel and geographic barriers that can limit access to RNS therapy, particularly for patients who live farther from epilepsy centers.
- Initiated enrollment in AURORA, a real-world evidence study designed to support expansion of the RNS System’s indication to adolescents aged 12–17 with drug-resistant focal epilepsy. Data collection is expected to be completed in early 2027, followed by analysis and submission to the FDA.
“Third-quarter revenue was below our expectations, and we have taken and are taking action to improve commercial execution and return the business to historical growth rates,” said
“Our innovation pipeline represents one of the most significant opportunities ahead for
Third Quarter 2026 Financial Results
RNS System revenue totaled
Non-GAAP gross margin for the third quarter of 2026 was 84.8%, compared with 82.8% in the third quarter of 2025. The slight year-over-year growth was driven by improved labor absorption. Total GAAP gross margin from continuing operations in the third quarter of 2026 was 84.3%.
Non-GAAP operating expenses in the third quarter of 2026 were
Non-GAAP sales and marketing expense in the third quarter of 2026 was
Non-GAAP research and development expense in the third quarter of 2026 was
Non-GAAP general and administrative expense in the third quarter of 2026 was
Non-GAAP income from operations was
The Company’s cash, cash equivalents, short-term investments and restricted cash balance as of
Full Year 2026 Financial Guidance
- Revise total revenue guidance for full year 2026 to between
$91 million and$92 million , representing underlying RNS growth of 10% to 11%. This compares to previously issued guidance of$99.5 million to$101.5 million . This guidance continues to reflect expected service revenue of approximately$1 million .
- Increase full year non-GAAP gross margin to between 83.0% and 83.5%, an increase compared to 82.0% to 83.0% previously.
- Revise full year non-GAAP operating expenses to be between
$85 million and$86 million , compared to previous guidance of$90 million to$92 million . This revised range continues to exclude approximately$10 million in stock-based compensation, a non-cash expense.
- Revise Adjusted EBITDA to be between
($8.5) million and($9.5) million compared to previous guidance between($7.5) million to($8.5) million .
Non-GAAP Measures
To supplement NeuroPace’s condensed financial statements presented in accordance with GAAP, the Company uses non-GAAP measures of certain components of financial performance. These non-GAAP measures include Adjusted EBITDA, non-GAAP gross margin, non-GAAP cost of goods sold, non-GAAP sales and marketing expense, non-GAAP research and development expense, non-GAAP general and administrative expense, non-GAAP operating expenses, non-GAAP income (loss) from operations, and non-GAAP net loss from operations.
Discontinued Operations & Basis of Presentation
The Company’s DIXI Medical product operations are presented as discontinued operations under ASC 205-20. Unless otherwise noted, the results discussed in this release reflect continuing operations; and prior-period amounts have been reclassified on a comparable basis, with no effect on previously reported net loss, total assets, total liabilities, or total stockholders’ equity. See the accompanying financial statements for the GAAP presentation of continuing and discontinued operations.
Webcast and Conference Call Information
About
Based in
Forward Looking Statements
This press release may contain forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as “aims,” “anticipates,” “believes,” “could,” “estimates,” “expects,” “forecasts,” “goal,” “intends,” “may,” “plans,” “possible,” “potential,” “seeks,” “will” and variations of these words or similar expressions that are intended to identify forward-looking statements, although not all forward-looking statements contain these words.
Condensed Statements of Operations and Comprehensive Loss (unaudited) | |||||||||||||||
| Three Months Ended |
| Nine Months Ended | ||||||||||||
(in thousands, except for share and per share amounts) |
| 2026 |
|
|
| 2025 |
|
|
| 2026 |
|
|
| 2025 |
|
Revenue | $ | 23,104 |
|
| $ | 23,351 |
|
| $ | 67,933 |
|
| $ | 61,173 |
|
Cost of goods sold |
| 3,633 |
|
|
| 4,181 |
|
|
| 11,545 |
|
|
| 10,659 |
|
Gross profit |
| 19,471 |
|
|
| 19,170 |
|
|
| 56,388 |
|
|
| 50,514 |
|
Operating expenses: |
|
|
|
|
|
|
| ||||||||
Sales and marketing |
| 11,169 |
|
|
| 12,025 |
|
|
| 34,876 |
|
|
| 33,919 |
|
Research and development |
| 6,166 |
|
|
| 6,576 |
|
|
| 20,253 |
|
|
| 20,861 |
|
General and administrative |
| 4,216 |
|
|
| 4,594 |
|
|
| 14,087 |
|
|
| 14,708 |
|
Total operating expenses |
| 21,551 |
|
|
| 23,195 |
|
|
| 69,216 |
|
|
| 69,488 |
|
Loss from continuing operations |
| (2,080 | ) |
|
| (4,025 | ) |
|
| (12,828 | ) |
|
| (18,974 | ) |
Interest income |
| 511 |
|
|
| 667 |
|
|
| 1,599 |
|
|
| 2,178 |
|
Interest expense |
| (1,565 | ) |
|
| (1,645 | ) |
|
| (4,625 | ) |
|
| (5,857 | ) |
Other income (expense), net |
| (164 | ) |
|
| 82 |
|
|
| (370 | ) |
|
| (486 | ) |
Net loss and comprehensive loss from continuing operations | $ | (3,298 | ) |
| $ | (4,921 | ) |
| $ | (16,224 | ) |
| $ | (23,139 | ) |
Net income from discontinued operations | $ | — |
|
| $ | 1,425 |
|
| $ | 37 |
|
| $ | 4,403 |
|
Net loss and comprehensive loss | $ | (3,298 | ) |
| $ | (3,496 | ) |
| $ | (16,187 | ) |
| $ | (18,736 | ) |
|
|
|
|
|
|
|
| ||||||||
Net loss per share from continuing operations attributable to common stockholders, basic and diluted | $ | (0.10 | ) |
| $ | (0.15 | ) |
| $ | (0.48 | ) |
| $ | (0.71 | ) |
Net income per share from discontinued operations attributable to common stockholders, basic and diluted | $ | 0.00 |
|
| $ | 0.04 |
|
| $ | 0.00 |
|
| $ | 0.13 |
|
Net loss per share attributable to common stockholders, basic and diluted | $ | (0.10 | ) |
| $ | (0.11 | ) |
| $ | (0.48 | ) |
| $ | (0.58 | ) |
Weighted-average shares used in computing net loss per share attributable to common stockholders, basic and diluted |
| 34,346,892 |
|
|
| 33,134,606 |
|
|
| 34,058,353 |
|
|
| 32,498,907 |
|
Condensed Balance Sheets (unaudited) | |||||||
|
| ||||||
(in thousands, except for share and per share amounts) |
| 2026 |
|
|
| 2025 |
|
Assets |
|
|
| ||||
Current assets: |
|
|
| ||||
Cash and cash equivalents | $ | 10,235 |
|
| $ | 21,692 |
|
Short-term investments |
| 38,996 |
|
|
| 39,366 |
|
Accounts receivable |
| 14,275 |
|
|
| 12,936 |
|
Inventory |
| 18,800 |
|
|
| 14,862 |
|
Prepaid expenses and other current assets |
| 2,234 |
|
|
| 1,438 |
|
Current assets of discontinued operations |
| — |
|
|
| 3,779 |
|
Total current assets |
| 84,540 |
|
|
| 94,073 |
|
Property and equipment, net |
| 1,164 |
|
|
| 1,125 |
|
Operating lease right-of-use asset |
| 8,740 |
|
|
| 10,132 |
|
Restricted cash |
| 242 |
|
|
| 122 |
|
Other assets |
| 89 |
|
|
| 113 |
|
Total assets | $ | 94,775 |
|
| $ | 105,565 |
|
Liabilities and Stockholders’ Equity |
|
|
| ||||
Current liabilities: |
|
|
| ||||
Accounts payable | $ | 3,240 |
|
| $ | 1,776 |
|
Accrued liabilities |
| 10,383 |
|
|
| 13,184 |
|
Operating lease liability |
| 2,327 |
|
|
| 2,117 |
|
Deferred revenue |
| 120 |
|
|
| 141 |
|
Current liabilities of discontinued operations |
| — |
|
|
| 596 |
|
Total current liabilities |
| 16,070 |
|
|
| 17,814 |
|
Long-term debt |
| 59,158 |
|
|
| 58,884 |
|
Operating lease liability, net of current portion |
| 8,055 |
|
|
| 9,836 |
|
Total liabilities |
| 83,283 |
|
|
| 86,534 |
|
Stockholders’ equity: |
|
|
| ||||
Common stock, |
| 34 |
|
|
| 34 |
|
Additional paid-in capital |
| 580,060 |
|
|
| 571,412 |
|
Accumulated deficit |
| (568,602 | ) |
|
| (552,415 | ) |
Total stockholders’ equity |
| 11,492 |
|
|
| 19,031 |
|
Total liabilities and stockholders’ equity | $ | 94,775 |
|
| $ | 105,565 |
|
Condensed Statements of Cash Flows (unaudited) | |||||||||||||||
| Three Months Ended |
| Nine Months Ended | ||||||||||||
(in thousands) |
| 2026 |
|
|
| 2025 |
|
|
| 2026 |
|
|
| 2025 |
|
Cash flows from operating activities |
|
|
|
|
|
|
| ||||||||
Net loss | $ | (3,298 | ) |
| $ | (3,496 | ) |
| $ | (16,187 | ) |
| $ | (18,736 | ) |
Adjustments to reconcile net loss to net cash used in operating activities: |
|
|
|
|
|
|
| ||||||||
Stock-based compensation expense |
| 2,430 |
|
|
| 2,628 |
|
|
| 7,011 |
|
|
| 8,482 |
|
Depreciation |
| 80 |
|
|
| 54 |
|
|
| 206 |
|
|
| 158 |
|
Amortization of debt discount and issuance costs |
| 71 |
|
|
| 70 |
|
|
| 209 |
|
|
| 174 |
|
Non-cash interest expense |
| 80 |
|
|
| 73 |
|
|
| 237 |
|
|
| 463 |
|
Loss on debt extinguishment |
| — |
|
|
| — |
|
|
| — |
|
|
| 527 |
|
Amortization of right-of-use asset |
| 475 |
|
|
| 433 |
|
|
| 1,392 |
|
|
| 1,268 |
|
Unrealized loss (gain) on short-term investments |
| 164 |
|
|
| (82 | ) |
|
| 370 |
|
|
| (41 | ) |
Inventory write-downs |
| 169 |
|
|
| 47 |
|
|
| 313 |
|
|
| 140 |
|
Loss on disposal of property and equipment |
| — |
|
|
| — |
|
|
| — |
|
|
| 2 |
|
Changes in operating assets and liabilities: |
|
|
|
|
|
|
| ||||||||
Accounts receivable |
| 655 |
|
|
| (1,383 | ) |
|
| 406 |
|
|
| (2,087 | ) |
Inventory |
| (858 | ) |
|
| (1,836 | ) |
|
| (2,218 | ) |
|
| (4,894 | ) |
Prepaid expenses and other assets |
| (780 | ) |
|
| (537 | ) |
|
| (794 | ) |
|
| 134 |
|
Accounts payable |
| (946 | ) |
|
| (48 | ) |
|
| 1,037 |
|
|
| 1,655 |
|
Accrued liabilities |
| (467 | ) |
|
| 2,650 |
|
|
| (2,956 | ) |
|
| 2,530 |
|
Deferred revenue |
| (3 | ) |
|
| (48 | ) |
|
| (21 | ) |
|
| 93 |
|
Operating lease liabilities |
| (535 | ) |
|
| (469 | ) |
|
| (1,571 | ) |
|
| (1,380 | ) |
Net cash used in operating activities |
| (2,763 | ) |
|
| (1,944 | ) |
|
| (12,566 | ) |
|
| (11,512 | ) |
Cash flows from investing activities |
|
|
|
|
|
|
| ||||||||
Acquisition of property and equipment |
| (16 | ) |
|
| (30 | ) |
|
| (258 | ) |
|
| (235 | ) |
Net cash used in investing activities |
| (16 | ) |
|
| (30 | ) |
|
| (258 | ) |
|
| (235 | ) |
Cash flows from financing activities |
|
|
|
|
|
|
| ||||||||
Proceeds from issuance of common stock in follow-on offering, net of underwriting discounts and commissions |
| — |
|
|
| (50 | ) |
|
| — |
|
|
| 69,654 |
|
Repurchase of common stock from |
| — |
|
|
| — |
|
|
| — |
|
|
| (49,546 | ) |
Proceeds from issuance of common stock under employee plans |
| 539 |
|
|
| 1 |
|
|
| 1,926 |
|
|
| 1,152 |
|
Taxes withheld and paid related to net share settlement of equity awards |
| (62 | ) |
|
| (53 | ) |
|
| (289 | ) |
|
| (455 | ) |
Proceeds from At-the-Market offering, net of sales commission |
| — |
|
|
| — |
|
|
| — |
|
|
| 232 |
|
Proceeds from debt, net of discounts and issuance costs |
| — |
|
|
| (133 | ) |
|
| — |
|
|
| 58,435 |
|
Payment of annual debt fee |
| — |
|
|
| — |
|
|
| (150 | ) |
|
| — |
|
Repayment of debt |
| — |
|
|
| — |
|
|
| — |
|
|
| (60,507 | ) |
Net cash provided by (used in) financing activities |
| 477 |
|
|
| (235 | ) |
|
| 1,487 |
|
|
| 18,965 |
|
Net increase (decrease) in cash and cash equivalents |
| (2,302 | ) |
|
| (2,209 | ) |
|
| (11,337 | ) |
|
| 7,218 |
|
Cash, cash equivalents and restricted cash at the Beginning of the Period |
| 12,779 |
|
|
| 22,979 |
|
|
| 21,814 |
|
|
| 13,552 |
|
Cash, cash equivalents and restricted cash at the End of the Period | $ | 10,477 |
|
| $ | 20,770 |
|
| $ | 10,477 |
|
| $ | 20,770 |
|
Reconciliation of cash, cash equivalents and restricted cash to balance sheets: |
|
|
|
|
|
|
| ||||||||
Cash and cash equivalents | $ | 10,235 |
|
| $ | 20,648 |
|
| $ | 10,235 |
|
| $ | 20,648 |
|
Restricted cash |
| 242 |
|
|
| 122 |
|
|
| 242 |
|
|
| 122 |
|
Cash, cash equivalents and restricted cash in balance sheets | $ | 10,477 |
|
| $ | 20,770 |
|
| $ | 10,477 |
|
| $ | 20,770 |
|
Table 1. 2025 GAAP to Non-GAAP Reconciliations from Continuing Operations (unaudited) | |||||||||||||||||||
| Three Months Ended |
| Year Ended | ||||||||||||||||
(in thousands) |
|
|
|
|
|
|
|
|
| ||||||||||
RNS revenue | $ | 18,151 |
|
| $ | 18,564 |
|
| $ | 22,580 |
|
| $ | 22,374 |
|
| $ | 81,669 |
|
Service revenue |
| 170 |
|
|
| 937 |
|
|
| 771 |
|
|
| 886 |
|
|
| 2,764 |
|
Revenue | $ | 18,321 |
|
| $ | 19,501 |
|
| $ | 23,351 |
|
| $ | 23,260 |
|
| $ | 84,433 |
|
|
|
|
|
|
|
|
|
|
| ||||||||||
GAAP cost of goods sold | $ | 3,190 |
|
| $ | 3,288 |
|
| $ | 4,181 |
|
| $ | 4,405 |
|
| $ | 15,064 |
|
Stock-based compensation |
| 178 |
|
|
| 173 |
|
|
| 168 |
|
|
| 175 |
|
|
| 694 |
|
Non-GAAP cost of goods sold | $ | 3,012 |
|
| $ | 3,115 |
|
| $ | 4,013 |
|
| $ | 4,230 |
|
| $ | 14,370 |
|
|
|
|
|
|
|
|
|
|
| ||||||||||
GAAP sales and marketing expense | $ | 10,405 |
|
| $ | 11,489 |
|
| $ | 12,025 |
|
| $ | 10,713 |
|
| $ | 44,632 |
|
Stock-based compensation |
| 783 |
|
|
| 761 |
|
|
| 781 |
|
|
| 727 |
|
|
| 3,052 |
|
Non-GAAP sales and marketing expense | $ | 9,622 |
|
| $ | 10,728 |
|
| $ | 11,244 |
|
| $ | 9,986 |
|
| $ | 41,580 |
|
|
|
|
|
|
|
|
|
|
| ||||||||||
GAAP research and development expense | $ | 7,440 |
|
| $ | 6,845 |
|
| $ | 6,576 |
|
| $ | 7,027 |
|
| $ | 27,888 |
|
Stock-based compensation |
| 872 |
|
|
| 865 |
|
|
| 821 |
|
|
| 848 |
|
|
| 3,406 |
|
Non-GAAP research and development expense | $ | 6,568 |
|
| $ | 5,980 |
|
| $ | 5,755 |
|
| $ | 6,179 |
|
| $ | 24,482 |
|
|
|
|
|
|
|
|
|
|
| ||||||||||
GAAP general and administrative expense | $ | 4,046 |
|
| $ | 6,068 |
|
| $ | 4,594 |
|
| $ | 4,382 |
|
| $ | 19,090 |
|
Stock-based compensation |
| 793 |
|
|
| 1,429 |
|
|
| 858 |
|
|
| 857 |
|
|
| 3,937 |
|
Non-GAAP general and administrative expense | $ | 3,253 |
|
| $ | 4,639 |
|
| $ | 3,736 |
|
| $ | 3,525 |
|
| $ | 15,153 |
|
|
|
|
|
|
|
|
|
|
| ||||||||||
GAAP operating expenses | $ | 21,891 |
|
| $ | 24,402 |
|
| $ | 23,195 |
|
| $ | 22,122 |
|
| $ | 91,610 |
|
Stock-based compensation |
| 2,448 |
|
|
| 3,055 |
|
|
| 2,460 |
|
|
| 2,432 |
|
|
| 10,395 |
|
Non-GAAP operating expenses | $ | 19,443 |
|
| $ | 21,347 |
|
| $ | 20,735 |
|
| $ | 19,690 |
|
| $ | 81,215 |
|
|
|
|
|
|
|
|
|
|
| ||||||||||
GAAP loss from continuing operations | $ | (6,760 | ) |
| $ | (8,189 | ) |
| $ | (4,025 | ) |
| $ | (3,267 | ) |
| $ | (22,241 | ) |
Stock-based compensation |
| 2,626 |
|
|
| 3,228 |
|
|
| 2,628 |
|
|
| 2,607 |
|
|
| 11,089 |
|
Non-GAAP loss from continuing operations | $ | (4,134 | ) |
| $ | (4,961 | ) |
| $ | (1,397 | ) |
| $ | (660 | ) |
| $ | (11,152 | ) |
Depreciation |
| 49 |
|
|
| 55 |
|
|
| 54 |
|
|
| 80 |
|
|
| 238 |
|
Adjusted EBITDA from continuing operations (Non-GAAP) | $ | (4,085 | ) |
| $ | (4,906 | ) |
| $ | (1,343 | ) |
| $ | (580 | ) |
| $ | (10,914 | ) |
|
|
|
|
|
|
|
|
|
| ||||||||||
GAAP loss from continuing operations | $ | (6,760 | ) |
| $ | (8,189 | ) |
| $ | (4,025 | ) |
| $ | (3,267 | ) |
| $ | (22,241 | ) |
Interest and other income (expense), net |
| (1,442 | ) |
|
| (1,827 | ) |
|
| (896 | ) |
|
| (962 | ) |
|
| (5,127 | ) |
GAAP net loss from continuing operations | $ | (8,202 | ) |
| $ | (10,016 | ) |
| $ | (4,921 | ) |
| $ | (4,229 | ) |
| $ | (27,368 | ) |
Stock-based compensation |
| 2,626 |
|
|
| 3,228 |
|
|
| 2,628 |
|
|
| 2,607 |
|
|
| 11,089 |
|
Non-GAAP net loss from continuing operations | $ | (5,576 | ) |
| $ | (6,788 | ) |
| $ | (2,293 | ) |
| $ | (1,622 | ) |
| $ | (16,279 | ) |
Table 2. 2026 GAAP to Non-GAAP Reconciliations from Continuing Operations (unaudited) | |||||||||||||||
| Three Months |
| Nine Months | ||||||||||||
(in thousands) |
|
|
|
|
|
|
| ||||||||
RNS revenue | $ | 21,689 |
|
| $ | 22,524 |
|
| $ | 22,901 |
|
| $ | 67,114 |
|
Service revenue |
| 314 |
|
|
| 302 |
|
|
| 203 |
|
|
| 819 |
|
Revenue | $ | 22,003 |
|
| $ | 22,826 |
|
| $ | 23,104 |
|
| $ | 67,933 |
|
|
|
|
|
|
|
|
| ||||||||
GAAP cost of goods sold | $ | 3,992 |
|
| $ | 3,920 |
|
| $ | 3,633 |
|
| $ | 11,545 |
|
Stock-based compensation |
| 138 |
|
|
| 126 |
|
|
| 118 |
|
|
| 382 |
|
Non-GAAP cost of goods sold | $ | 3,854 |
|
| $ | 3,794 |
|
| $ | 3,515 |
|
| $ | 11,163 |
|
|
|
|
|
|
|
|
| ||||||||
GAAP sales and marketing expense | $ | 11,583 |
|
| $ | 12,124 |
|
| $ | 11,169 |
|
| $ | 34,876 |
|
Stock-based compensation |
| 595 |
|
|
| 650 |
|
|
| 656 |
|
|
| 1,901 |
|
Non-GAAP sales and marketing expense | $ | 10,988 |
|
| $ | 11,474 |
|
| $ | 10,513 |
|
| $ | 32,975 |
|
|
|
|
|
|
|
|
| ||||||||
GAAP research and development expense | $ | 7,189 |
|
| $ | 6,898 |
|
| $ | 6,166 |
|
| $ | 20,253 |
|
Stock-based compensation |
| 713 |
|
|
| 624 |
|
|
| 647 |
|
|
| 1,984 |
|
Non-GAAP research and development expense | $ | 6,476 |
|
| $ | 6,274 |
|
| $ | 5,519 |
|
| $ | 18,269 |
|
|
|
|
|
|
|
|
| ||||||||
GAAP general and administrative expense | $ | 4,844 |
|
| $ | 5,027 |
|
| $ | 4,216 |
|
| $ | 14,087 |
|
Stock-based compensation |
| 832 |
|
|
| 903 |
|
|
| 1,009 |
|
|
| 2,744 |
|
Non-GAAP general and administrative expense | $ | 4,012 |
|
| $ | 4,124 |
|
| $ | 3,207 |
|
| $ | 11,343 |
|
|
|
|
|
|
|
|
| ||||||||
GAAP operating expenses | $ | 23,616 |
|
| $ | 24,049 |
|
| $ | 21,551 |
|
| $ | 69,216 |
|
Stock-based compensation |
| 2,140 |
|
|
| 2,177 |
|
|
| 2,312 |
|
|
| 6,629 |
|
Non-GAAP operating expenses | $ | 21,476 |
|
| $ | 21,872 |
|
| $ | 19,239 |
|
| $ | 62,587 |
|
|
|
|
|
|
|
|
| ||||||||
GAAP loss from continuing operations | $ | (5,605 | ) |
| $ | (5,143 | ) |
| $ | (2,080 | ) |
| $ | (12,828 | ) |
Stock-based compensation |
| 2,278 |
|
|
| 2,303 |
|
|
| 2,430 |
|
|
| 7,011 |
|
Non-GAAP income (loss) from continuing operations | $ | (3,327 | ) |
| $ | (2,840 | ) |
| $ | 350 |
|
| $ | (5,817 | ) |
Depreciation |
| 60 |
|
|
| 66 |
|
|
| 80 |
|
|
| 206 |
|
Adjusted EBITDA from continuing operations (Non-GAAP) | $ | (3,267 | ) |
| $ | (2,774 | ) |
| $ | 430 |
|
| $ | (5,611 | ) |
|
|
|
|
|
|
|
| ||||||||
GAAP loss from continuing operations | $ | (5,605 | ) |
| $ | (5,143 | ) |
| $ | (2,080 | ) |
| $ | (12,828 | ) |
Interest and other income (expense), net |
| (1,121 | ) |
|
| (1,057 | ) |
|
| (1,218 | ) |
|
| (3,396 | ) |
GAAP net loss from continuing operations | $ | (6,726 | ) |
| $ | (6,200 | ) |
| $ | (3,298 | ) |
| $ | (16,224 | ) |
Stock-based compensation |
| 2,278 |
|
|
| 2,303 |
|
|
| 2,430 |
|
|
| 7,011 |
|
Non-GAAP net loss from continuing operations | $ | (4,448 | ) |
| $ | (3,897 | ) |
| $ | (868 | ) |
| $ | (9,213 | ) |
Table 3. GAAP to Non-GAAP Reconciliations 2026 Revised Guidance | ||
(in thousands) | 2026 Guidance | |
RNS revenue | ||
Service revenue | ~1,000 | |
Revenue | ||
|
| |
GAAP gross margin | 83.0% | |
Stock-based compensation | ~50 bps | |
Non-GAAP gross margin | 83.0% to 83.5% | |
|
| |
GAAP sales and marketing expense | ||
Stock-based compensation | ~3,000 | |
Non-GAAP sales and marketing expense | ||
|
| |
GAAP research and development expense | ||
Stock-based compensation | ~3,000 | |
Non-GAAP research and development expense | ||
|
| |
GAAP general and administrative expense | ||
Stock-based compensation | ~4,000 | |
Non-GAAP general and administrative expense | ||
|
| |
GAAP operating expenses | ||
Stock-based compensation | ~10,000 | |
Non-GAAP operating expenses | ||
|
| |
GAAP loss from operations | ( | |
Stock-based compensation (including gross margin) | ~10,500 | |
Non-GAAP loss from operations | (8,750) to (9,750) | |
Depreciation | ~250 | |
Adjusted EBITDA (Non-GAAP) | ( | |
View source version on businesswire.com: https://www.businesswire.com/news/home/20261112017708/en/
Investor Contact:
Vice President, Finance and Investor Relations
sschaper@neuropace.com
investors@neuropace.com
Source: